首页> 外文期刊>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics >Past administration of beta-lactam antibiotics and increase in the emergence of beta-lactamase-producing bacteria in patients with orofacial odontogenic infections.
【24h】

Past administration of beta-lactam antibiotics and increase in the emergence of beta-lactamase-producing bacteria in patients with orofacial odontogenic infections.

机译:过去曾使用过β-内酰胺类抗生素并增加了口腔性牙源性感染患者的产生β-内酰胺酶的细菌的出现。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The purpose of this study was to determine the current status of beta-lactamase-producing bacteria in orofacial odontogenic infections. STUDY DESIGN: Microbiologic data regarding purulent exudate from 111 cases with orofacial odontogenic infections were analyzed in relation to the past administration of beta-lactams. RESULTS: beta-lactamase-producing bacteria were isolated more frequently from the beta-lactam-administered group (38.5%) than from the beta-lactam-nonadministered group (10.9%; P <.005), and they were isolated more frequently as the duration of administration increased. The predominant bacteria isolated included Prevotella (the most frequent isolate), viridans streptococci, Peptostreptococcus, and Fusobacterium, and 7.1% of total isolates produced beta-lactamase. Penicillin and cefazolin worked well with beta-lactamase-nonproducing Prevotella but were remarkably affected by beta-lactamase-producing Prevotella. Cefmetazole, sulbactam/cefoperazone, and imipenem worked well against both types of Prevotella. CONCLUSIONS: beta-lactams are still suitable for the first antimicrobial therapy in the treatment of these infections. However, because past beta-lactam administration increases the emergence of beta-lactamase-producing bacteria, beta-lactamase-stable antibiotics should be prescribed to patients with unresolved infections who have received beta-lactams.
机译:目的:本研究的目的是确定口腔颌面牙源性感染中产生β-内酰胺酶的细菌的现状。研究设计:分析了111例口腔颌面牙源性感染的化脓性分泌物的微生物学数据,与过去服用β-内酰胺有关。结果:与不使用β-内酰胺酶的组(10.9%; P <.005)相比,使用β-内酰胺酶的组(38.5%)更容易分离出产生β-内酰胺酶的细菌。给药时间延长。分离出的主要细菌包括普雷沃氏菌(最常见的分离株),绿色弧菌链球菌,Peptostreptococcus和Fusobacter,总分离株中有7.1%产生了β-内酰胺酶。青霉素和头孢唑啉与不产生β-内酰胺酶的普氏杆菌共存良好,但明显受到产生β-内酰胺酶的普氏菌的影响。头孢美唑,舒巴坦/头孢哌酮和亚胺培南对两种类型的普瑞沃氏菌都有效。结论:β-内酰胺类仍然适合于治疗这些感染的第一种抗菌疗法。但是,由于过去使用β-内酰胺会增加产生β-内酰胺酶的细菌的出现,因此对于接受了β-内酰胺治疗的未解决感染的患者,应开具β-内酰胺酶稳定的抗生素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号